of intentions and documentation of each item in the bundle checklist. The baseline cohort comprised 40 patients (21 male, 19 female; median age 60 [38-83]), with a further 40 patients included in the second cycle (25 male, 15 female; median age 45 [33-65]). Hepatic encephalopathy (63%, n=25) and ascites (70%, n=28) were commonest reasons for admission. Introduction of the bundle led to improvements in several areas. 80% of appropriate patients had an out-patient paracentesis procedure booked prior to discharge after bundle introduction, compared to just 7.7%; p<0.001) beforehand. Likewise, variceal screening endoscopy was arranged for 50% post-bundle (27.5% pre-bundle; p=0.21), and more of those with recently identified varices were appropriately discharged on primary prophylaxis (50% vs 37.5%; p=0.26). Patients admitted with hepatic encephalopathy were more likely to be discharged with appropriate lactulose (93% vs 40%; p<0.0001) and Rifaximin (63% vs 22.5%; p<0.0001). Those with alcohol related liver disease had improved rates of planned community follow-up (83% vs 11%; p<0.0001) and documented need for abstinence (100% vs 30%; p<0.0001). Finally, communication was also improved, both for advice to primary care about renal function (documented in 70% vs 8.8%; p<0.001), and explanation of the need for specific medications (50% vs 12.5%; p<0.0001).

Conclusion Implementation of the discharge bundle led to improved discharge planning and documentation, justifying the continued use of the checklist for patients hospitalized with DCLD.

PWE-31 USE OF NON-SELECTIVE BETA-BLOCKERS (NSBB) IS NOT DETRIMENTAL IN CIRRHOTIC PATIENTS WITH SEVERE ASCITES

Chaonan Dong*, Alice Weidner, Rohit Sinha. Sunderland Royal Hospital, Sunderland, UK

Introduction The use of non-selective beta-blockers (NSBB) is the cornerstone in the treatment of portal hypertension. Despite convincing data, scepticism surrounding safety of NSBB, particularly in severe ascites remains. We aim to study the survival outcome in patients with liver cirrhosis and severe ascites on NSBB.

Methods This was a single-centre retrospective study of 131 patients with liver cirrhosis and ascites who presented consecutively from January 2014 to December 2019 by attending nurse-led large volume paracentesis (LVP) service at the Sunderland Royal Hospital. Data was obtained from patient notes using Meditech™ patient database. Survival was calculated from the date when first LVP was performed. Two time-varying covariates, Transjugular Intrahepatic Porto-Systemic Shunt (TIPSS) and liver transplant, which occurred during the follow-up period were included in the adjusted analysis. Cox regression was used to compare the survival times in the two groups, both before and after adjustments for potential confounders.

Results Patient characteristics and other observed variables were comparable in the NSBB (n=47) and No-NSBB (n=84) group. Alcohol was the commonest aetiology of cirrhosis and comparable (p=0.72) across groups, 87% and 89% of NSBB and no-NSBB group respectively. 66% and 64% of patients continued to drink alcohol in the NSBB and no-NSBB group (p=0.85). Refractory ascites was present and comparable (p=0.76) in 68% and 65% of the NSBB and no-NSBB group respectively. The frequency of LVP was comparable between the groups (p=0.13). The median MELD was comparable (p=0.65) at 15.2 [11.8, 18.7] and 15.0 [10.3, 18.4] in the NSBB and no-NSBB groups. There was no statistically
significant difference in survival between the two groups (p=0.24) as seen in figure 1. The adjusted hazard risk analysis (0.75 [95%CI 0.51, 1.11], p=0.15) suggested weak evidence of a difference in survival between the two groups. Median survival times were slightly longer in the NSBB group, 88.8 months (95% CI 53.2, 124.4) compared with No-NSBB group 61.4 months (95% CI 26.6, 96.2); and the risk of death at any time lower. TIPSS was performed in 6 patients of No-NSBB and 4 with NSBB group. Two patients received liver transplant, both in the no-NSBB group. Diuretic intractable ascites (p=0.06), MELD (p=0.018) and frequency LVP sessions (p<0.001) were all independent predictors of mortality.

Conclusions Our study demonstrates that NSBB is safe in cirrhotic patients with severe ascites, and it is not associated with detrimental outcome. There is need for a randomised controlled trial to draw conclusive evidence.

PWE-32 THE EFFECTIVENESS OF HEPATOCELLULAR CARCINOMA SURVEILLANCE DURING COVID-19

Introduction The incidence of hepatocellular carcinoma (HCC) in Wales is rising. We aimed to evaluate the impact of the COVID-19 pandemic on the South Wales HCC multi-disciplinary meeting (MDM) referrals and patient management.

Methods Baseline patient characteristics at MDM and treatment information was collated for index HCC discussion from the electronic health record. The year of the COVID period (CP) 01/03/2020-28/2/2021, was compared to the pre-pandemic period (PP) 01/03/2018-29/02/2020. To determine significance, a Chi² analysis or Fisher’s Exact test were used where appropriate.

Results There was a 3-fold increase in index HCC diagnoses in South Wales MDM between 2002 and 2018. 803 patients were discussed from March 2018-21; follow up (372) and non-HCC (90) cases were excluded. There were 245 PP and 96 CP index HCC diagnoses; a 22% reduction in annual index HCC diagnoses in the COVID period. The absolute number of HCCs detected by surveillance remained consistent at 33 per annum in PP and CP periods (27% v 34% respectively). During CP the proportion of patients offered best supportive care and undergoing further investigation increased (47 to 56% and 1.2 to 13.5% respectively) whilst all anti-cancer interventions fell (22 to 15.6%, chemo-embolisation (21.2 to 11.5%) and systemic anti-cancer therapies (8.2 to 3.1%, p<0.0001). However, during CP a greater proportion of those on HCC surveillance received curative therapies compared to HCC detected in individuals with cirrhosis outside of screening (27.3 vs. 8.5%, p=0.03). Median time from point of suspicion of HCC to...